Company: SNY
Filing Date: 2025-02-13
Form Type: 20-F
Source: 0001121404-25-000010
Chunk: 476

Company: Sanofi
Filing Date: 2025-02-13
Form: 20-F
Chunk 476
---
| Share of profit/(loss) from investments accounted for using the equity method |       101 |     — |     101 |
| Net income attributable to non-controlling interests                          |       -18 |     — |     -18 |
| Business operating income                                                     |    11,155 |    23 |  11,178 |

(a) Figures for the comparative period (2023) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued

operation.

| F-96 | SANOFIFORM 20-F2024 |

| NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS |

|                                                                               | 2022(a)(b) |       |         |
| (€ million)                                                                   |  Biopharma | Other |   Total |
| Net sales                                                                     |     37,651 |     — |  37,651 |
| Other revenues                                                                |      2,534 |   376 |   2,910 |
| Cost of sales                                                                 |    -11,682 |  -197 | -11,879 |
| Research and development expenses                                             |     -6,499 |    -2 |  -6,501 |
| Selling and general expenses                                                  |     -8,536 |  -203 |  -8,739 |
| Other operating income and expenses                                           |       -764 |    55 |    -709 |
| Share of profit/(loss) from investments accounted for using the equity method |         76 |     — |      76 |
| Net income attributable to non-controlling interests                          |        -16 |     — |     -16 |
| Business operating income                                                     |     12,764 |    29 |  12,793 |

(a) Figures for the comparative period (2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued

operation.

(b) 2022 business operating income has been recast from the amount previously reported to include the one-time income of € 952 million from the Libtayo

transaction (€ 706million net of tax).

The table below, presented in compliance with IFRS 8, shows a reconciliation between aggregated “Business operating income”

for the segment and Income before tax and investments accounted for using the equity method :

| (€ million)                                                                      |   2024 | 2023(a) | 2022(a)(h) |
| Business operating income                                                        |